Search

Your search keyword '"Valenti, Melanie"' showing total 139 results
Start Over Author "Valenti, Melanie" Publication Year Range Last 3 years
139 results on '"Valenti, Melanie"'

1. Supplementary Figure S5 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

2. Supplementary Video S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

3. Supplementary Tables S1-S19 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

4. Supplementary Methods S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

5. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, additional, Cunningham, David, additional, Schirripa, Marta, additional, Lampis, Andrea, additional, Hahne, Jens C., additional, Tunariu, Nina, additional, Hong, Sung Pil, additional, Marchetti, Silvia, additional, Khan, Khurum, additional, Fontana, Elisa, additional, Angerilli, Valentina, additional, Delrieux, Mia, additional, Nava Rodrigues, Daniel, additional, Procaccio, Letizia, additional, Rao, Sheela, additional, Watkins, David, additional, Starling, Naureen, additional, Chau, Ian, additional, Braconi, Chiara, additional, Fotiadis, Nicos, additional, Begum, Ruwaida, additional, Guppy, Naomy, additional, Howell, Louise, additional, Valenti, Melanie, additional, Cribbes, Scott, additional, Kolozsvari, Bernadett, additional, Kirkin, Vladimir, additional, Lonardi, Sara, additional, Ghidini, Michele, additional, Passalacqua, Rodolfo, additional, Elghadi, Raghad, additional, Magnani, Luca, additional, Pinato, David J., additional, Di Maggio, Federica, additional, Ghelardi, Filippo, additional, Sottotetti, Elisa, additional, Vetere, Guglielmo, additional, Ciracì, Paolo, additional, Vlachogiannis, Georgios, additional, Pietrantonio, Filippo, additional, Cremolini, Chiara, additional, Cortellini, Alessio, additional, Loupakis, Fotios, additional, Fassan, Matteo, additional, and Valeri, Nicola, additional

Published
2024
Full Text
View/download PDF

6. Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones

Author

Harnden, Alice C., primary, Davis, Owen A., additional, Box, Gary M., additional, Hayes, Angela, additional, Johnson, Louise D., additional, Henley, Alan T., additional, de Haven Brandon, Alexis K., additional, Valenti, Melanie, additional, Cheung, Kwai-Ming J., additional, Brennan, Alfie, additional, Huckvale, Rosemary, additional, Pierrat, Olivier A., additional, Talbot, Rachel, additional, Bright, Michael D., additional, Akpinar, Hafize Aysin, additional, Miller, Daniel S. J., additional, Tarantino, Dalia, additional, Gowan, Sharon, additional, de Klerk, Selby, additional, McAndrew, Peter Craig, additional, Le Bihan, Yann-Vaï, additional, Meniconi, Mirco, additional, Burke, Rosemary, additional, Kirkin, Vladimir, additional, van Montfort, Rob L. M., additional, Raynaud, Florence I., additional, Rossanese, Olivia W., additional, Bellenie, Benjamin R., additional, and Hoelder, Swen, additional

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 1 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Author

Ang, Joo Ern, primary, Pandher, Rupinder, primary, Ang, Joo Chew, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de Haven Brandon, Alexis, primary, Baird, Richard D., primary, Friedman, Lori, primary, Derynck, Mika, primary, Vanhaesebroeck, Bart, primary, Eccles, Suzanne A., primary, Kaye, Stan B., primary, Workman, Paul, primary, de Bono, Johann S., primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 1 from Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Author

Ang, Joo Ern, primary, Pal, Akos, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de haven Brandon, Alexis, primary, Revell, Victoria L., primary, Skene, Debra J., primary, Venturi, Miro, primary, Rueger, Ruediger, primary, Meresse, Valerie, primary, Eccles, Suzanne A., primary, de Bono, Johann S., primary, Kaye, Stanley B., primary, Workman, Paul, primary, Banerji, Udai, primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 3 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Author

Ang, Joo Ern, primary, Pandher, Rupinder, primary, Ang, Joo Chew, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de Haven Brandon, Alexis, primary, Baird, Richard D., primary, Friedman, Lori, primary, Derynck, Mika, primary, Vanhaesebroeck, Bart, primary, Eccles, Suzanne A., primary, Kaye, Stan B., primary, Workman, Paul, primary, de Bono, Johann S., primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 1 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Author

Ang, Joo Ern, primary, Pandher, Rupinder, primary, Ang, Joo Chew, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de Haven Brandon, Alexis, primary, Baird, Richard D., primary, Friedman, Lori, primary, Derynck, Mika, primary, Vanhaesebroeck, Bart, primary, Eccles, Suzanne A., primary, Kaye, Stan B., primary, Workman, Paul, primary, de Bono, Johann S., primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 5 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Author

Ang, Joo Ern, primary, Pandher, Rupinder, primary, Ang, Joo Chew, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de Haven Brandon, Alexis, primary, Baird, Richard D., primary, Friedman, Lori, primary, Derynck, Mika, primary, Vanhaesebroeck, Bart, primary, Eccles, Suzanne A., primary, Kaye, Stan B., primary, Workman, Paul, primary, de Bono, Johann S., primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

12. Data from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Author

Bielen, Aleksandra, primary, Perryman, Lara, primary, Box, Gary M., primary, Valenti, Melanie, primary, de Haven Brandon, Alexis, primary, Martins, Vanessa, primary, Jury, Alexa, primary, Popov, Sergey, primary, Gowan, Sharon, primary, Jeay, Sebastien, primary, Raynaud, Florence I., primary, Hofmann, Francesco, primary, Hargrave, Darren, primary, Eccles, Suzanne A., primary, and Jones, Chris, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 1 from Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Author

Ang, Joo Ern, primary, Pal, Akos, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de haven Brandon, Alexis, primary, Revell, Victoria L., primary, Skene, Debra J., primary, Venturi, Miro, primary, Rueger, Ruediger, primary, Meresse, Valerie, primary, Eccles, Suzanne A., primary, de Bono, Johann S., primary, Kaye, Stanley B., primary, Workman, Paul, primary, Banerji, Udai, primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figures 1-4 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

Author

Yap, Timothy A., primary, Walton, Mike I., primary, Hunter, Lisa-Jane K., primary, Valenti, Melanie, primary, de Haven Brandon, Alexis, primary, Eve, Paul D., primary, Ruddle, Ruth, primary, Heaton, Simon P., primary, Henley, Alan, primary, Pickard, Lisa, primary, Vijayaraghavan, Gowri, primary, Caldwell, John J., primary, Thompson, Neil T., primary, Aherne, Wynne, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Workman, Paul, primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

15. Data from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Author

Ang, Joo Ern, primary, Pandher, Rupinder, primary, Ang, Joo Chew, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de Haven Brandon, Alexis, primary, Baird, Richard D., primary, Friedman, Lori, primary, Derynck, Mika, primary, Vanhaesebroeck, Bart, primary, Eccles, Suzanne A., primary, Kaye, Stan B., primary, Workman, Paul, primary, de Bono, Johann S., primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

16. Data from Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Author

Ang, Joo Ern, primary, Pal, Akos, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de haven Brandon, Alexis, primary, Revell, Victoria L., primary, Skene, Debra J., primary, Venturi, Miro, primary, Rueger, Ruediger, primary, Meresse, Valerie, primary, Eccles, Suzanne A., primary, de Bono, Johann S., primary, Kaye, Stanley B., primary, Workman, Paul, primary, Banerji, Udai, primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 4 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Author

Ang, Joo Ern, primary, Pandher, Rupinder, primary, Ang, Joo Chew, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de Haven Brandon, Alexis, primary, Baird, Richard D., primary, Friedman, Lori, primary, Derynck, Mika, primary, Vanhaesebroeck, Bart, primary, Eccles, Suzanne A., primary, Kaye, Stan B., primary, Workman, Paul, primary, de Bono, Johann S., primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 1 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Author

Bielen, Aleksandra, primary, Perryman, Lara, primary, Box, Gary M., primary, Valenti, Melanie, primary, de Haven Brandon, Alexis, primary, Martins, Vanessa, primary, Jury, Alexa, primary, Popov, Sergey, primary, Gowan, Sharon, primary, Jeay, Sebastien, primary, Raynaud, Florence I., primary, Hofmann, Francesco, primary, Hargrave, Darren, primary, Eccles, Suzanne A., primary, and Jones, Chris, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 3 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Author

Bielen, Aleksandra, primary, Perryman, Lara, primary, Box, Gary M., primary, Valenti, Melanie, primary, de Haven Brandon, Alexis, primary, Martins, Vanessa, primary, Jury, Alexa, primary, Popov, Sergey, primary, Gowan, Sharon, primary, Jeay, Sebastien, primary, Raynaud, Florence I., primary, Hofmann, Francesco, primary, Hargrave, Darren, primary, Eccles, Suzanne A., primary, and Jones, Chris, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 4 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Author

Bielen, Aleksandra, primary, Perryman, Lara, primary, Box, Gary M., primary, Valenti, Melanie, primary, de Haven Brandon, Alexis, primary, Martins, Vanessa, primary, Jury, Alexa, primary, Popov, Sergey, primary, Gowan, Sharon, primary, Jeay, Sebastien, primary, Raynaud, Florence I., primary, Hofmann, Francesco, primary, Hargrave, Darren, primary, Eccles, Suzanne A., primary, and Jones, Chris, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 2 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Author

Bielen, Aleksandra, primary, Perryman, Lara, primary, Box, Gary M., primary, Valenti, Melanie, primary, de Haven Brandon, Alexis, primary, Martins, Vanessa, primary, Jury, Alexa, primary, Popov, Sergey, primary, Gowan, Sharon, primary, Jeay, Sebastien, primary, Raynaud, Florence I., primary, Hofmann, Francesco, primary, Hargrave, Darren, primary, Eccles, Suzanne A., primary, and Jones, Chris, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 2 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Author

Ang, Joo Ern, primary, Pandher, Rupinder, primary, Ang, Joo Chew, primary, Asad, Yasmin J., primary, Henley, Alan T., primary, Valenti, Melanie, primary, Box, Gary, primary, de Haven Brandon, Alexis, primary, Baird, Richard D., primary, Friedman, Lori, primary, Derynck, Mika, primary, Vanhaesebroeck, Bart, primary, Eccles, Suzanne A., primary, Kaye, Stan B., primary, Workman, Paul, primary, de Bono, Johann S., primary, and Raynaud, Florence I., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure Legends 1-4 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Author

Bielen, Aleksandra, primary, Perryman, Lara, primary, Box, Gary M., primary, Valenti, Melanie, primary, de Haven Brandon, Alexis, primary, Martins, Vanessa, primary, Jury, Alexa, primary, Popov, Sergey, primary, Gowan, Sharon, primary, Jeay, Sebastien, primary, Raynaud, Florence I., primary, Hofmann, Francesco, primary, Hargrave, Darren, primary, Eccles, Suzanne A., primary, and Jones, Chris, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 5A from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Author

Yap, Timothy A., primary, Walton, Mike I., primary, Grimshaw, Kyla M., primary, te Poele, Robert H., primary, Eve, Paul D., primary, Valenti, Melanie R., primary, de Haven Brandon, Alexis K., primary, Martins, Vanessa, primary, Zetterlund, Anna, primary, Heaton, Simon P., primary, Heinzmann, Kathrin, primary, Jones, Paul S., primary, Feltell, Ruth E., primary, Reule, Matthias, primary, Woodhead, Steven J., primary, Davies, Thomas G., primary, Lyons, John F., primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Workman, Paul, primary, Thompson, Neil T., primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table and Figures from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

Author

Renshaw, Jane, primary, Taylor, Kathryn R., primary, Bishop, Ryan, primary, Valenti, Melanie, primary, De Haven Brandon, Alexis, primary, Gowan, Sharon, primary, Eccles, Suzanne A., primary, Ruddle, Ruth R., primary, Johnson, Louise D., primary, Raynaud, Florence I., primary, Selfe, Joanna L., primary, Thway, Khin, primary, Pietsch, Torsten, primary, Pearson, Andrew D., primary, and Shipley, Janet, primary

Published
2023
Full Text
View/download PDF

26. CCR Translation for This Article from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

Author

Renshaw, Jane, primary, Taylor, Kathryn R., primary, Bishop, Ryan, primary, Valenti, Melanie, primary, De Haven Brandon, Alexis, primary, Gowan, Sharon, primary, Eccles, Suzanne A., primary, Ruddle, Ruth R., primary, Johnson, Louise D., primary, Raynaud, Florence I., primary, Selfe, Joanna L., primary, Thway, Khin, primary, Pietsch, Torsten, primary, Pearson, Andrew D., primary, and Shipley, Janet, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 5 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Author

Walton, Mike I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie R., primary, De Haven Brandon, Alexis K., primary, Box, Gary, primary, Hallsworth, Albert, primary, Smith, Elizabeth L., primary, Boxall, Kathy J., primary, Lainchbury, Michael, primary, Matthews, Thomas P., primary, Jamin, Yann, primary, Robinson, Simon P., primary, Aherne, G. Wynne, primary, Reader, John C., primary, Chesler, Louis, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 2 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Author

Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Patel, Sonal, primary, Alix, Sonia, primary, Box, Gary, primary, Chuckowree, Irina, primary, Folkes, Adrian, primary, Gowan, Sharon, primary, De Haven Brandon, Alexis, primary, Di Stefano, Francesca, primary, Hayes, Angela, primary, Henley, Alan T., primary, Lensun, Letitia, primary, Pergl-Wilson, Giles, primary, Robson, Anthony, primary, Saghir, Nahid, primary, Zhyvoloup, Alexander, primary, McDonald, Edward, primary, Sheldrake, Peter, primary, Shuttleworth, Stephen, primary, Valenti, Melanie, primary, Wan, Nan Chi, primary, Clarke, Paul A., primary, and Workman, Paul, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 6A from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Author

Yap, Timothy A., primary, Walton, Mike I., primary, Grimshaw, Kyla M., primary, te Poele, Robert H., primary, Eve, Paul D., primary, Valenti, Melanie R., primary, de Haven Brandon, Alexis K., primary, Martins, Vanessa, primary, Zetterlund, Anna, primary, Heaton, Simon P., primary, Heinzmann, Kathrin, primary, Jones, Paul S., primary, Feltell, Ruth E., primary, Reule, Matthias, primary, Woodhead, Steven J., primary, Davies, Thomas G., primary, Lyons, John F., primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Workman, Paul, primary, Thompson, Neil T., primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 3 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Author

Walton, Mike I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie R., primary, De Haven Brandon, Alexis K., primary, Box, Gary, primary, Hallsworth, Albert, primary, Smith, Elizabeth L., primary, Boxall, Kathy J., primary, Lainchbury, Michael, primary, Matthews, Thomas P., primary, Jamin, Yann, primary, Robinson, Simon P., primary, Aherne, G. Wynne, primary, Reader, John C., primary, Chesler, Louis, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 4 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Author

Walton, Mike I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie R., primary, De Haven Brandon, Alexis K., primary, Box, Gary, primary, Hallsworth, Albert, primary, Smith, Elizabeth L., primary, Boxall, Kathy J., primary, Lainchbury, Michael, primary, Matthews, Thomas P., primary, Jamin, Yann, primary, Robinson, Simon P., primary, Aherne, G. Wynne, primary, Reader, John C., primary, Chesler, Louis, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure Legend from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Author

Walton, Mike I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie R., primary, De Haven Brandon, Alexis K., primary, Box, Gary, primary, Hallsworth, Albert, primary, Smith, Elizabeth L., primary, Boxall, Kathy J., primary, Lainchbury, Michael, primary, Matthews, Thomas P., primary, Jamin, Yann, primary, Robinson, Simon P., primary, Aherne, G. Wynne, primary, Reader, John C., primary, Chesler, Louis, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figures 1-7, Tables 1-4 from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Author

Yap, Timothy A., primary, Walton, Mike I., primary, Grimshaw, Kyla M., primary, te Poele, Robert H., primary, Eve, Paul D., primary, Valenti, Melanie R., primary, de Haven Brandon, Alexis K., primary, Martins, Vanessa, primary, Zetterlund, Anna, primary, Heaton, Simon P., primary, Heinzmann, Kathrin, primary, Jones, Paul S., primary, Feltell, Ruth E., primary, Reule, Matthias, primary, Woodhead, Steven J., primary, Davies, Thomas G., primary, Lyons, John F., primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Workman, Paul, primary, Thompson, Neil T., primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 1 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Author

Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Patel, Sonal, primary, Alix, Sonia, primary, Box, Gary, primary, Chuckowree, Irina, primary, Folkes, Adrian, primary, Gowan, Sharon, primary, De Haven Brandon, Alexis, primary, Di Stefano, Francesca, primary, Hayes, Angela, primary, Henley, Alan T., primary, Lensun, Letitia, primary, Pergl-Wilson, Giles, primary, Robson, Anthony, primary, Saghir, Nahid, primary, Zhyvoloup, Alexander, primary, McDonald, Edward, primary, Sheldrake, Peter, primary, Shuttleworth, Stephen, primary, Valenti, Melanie, primary, Wan, Nan Chi, primary, Clarke, Paul A., primary, and Workman, Paul, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table & Figure Legends from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

Author

Renshaw, Jane, primary, Taylor, Kathryn R., primary, Bishop, Ryan, primary, Valenti, Melanie, primary, De Haven Brandon, Alexis, primary, Gowan, Sharon, primary, Eccles, Suzanne A., primary, Ruddle, Ruth R., primary, Johnson, Louise D., primary, Raynaud, Florence I., primary, Selfe, Joanna L., primary, Thway, Khin, primary, Pietsch, Torsten, primary, Pearson, Andrew D., primary, and Shipley, Janet, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 3A from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Author

Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Patel, Sonal, primary, Alix, Sonia, primary, Box, Gary, primary, Chuckowree, Irina, primary, Folkes, Adrian, primary, Gowan, Sharon, primary, De Haven Brandon, Alexis, primary, Di Stefano, Francesca, primary, Hayes, Angela, primary, Henley, Alan T., primary, Lensun, Letitia, primary, Pergl-Wilson, Giles, primary, Robson, Anthony, primary, Saghir, Nahid, primary, Zhyvoloup, Alexander, primary, McDonald, Edward, primary, Sheldrake, Peter, primary, Shuttleworth, Stephen, primary, Valenti, Melanie, primary, Wan, Nan Chi, primary, Clarke, Paul A., primary, and Workman, Paul, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 1 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Author

Walton, Mike I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie R., primary, De Haven Brandon, Alexis K., primary, Box, Gary, primary, Hallsworth, Albert, primary, Smith, Elizabeth L., primary, Boxall, Kathy J., primary, Lainchbury, Michael, primary, Matthews, Thomas P., primary, Jamin, Yann, primary, Robinson, Simon P., primary, Aherne, G. Wynne, primary, Reader, John C., primary, Chesler, Louis, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 2 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Author

Walton, Mike I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie R., primary, De Haven Brandon, Alexis K., primary, Box, Gary, primary, Hallsworth, Albert, primary, Smith, Elizabeth L., primary, Boxall, Kathy J., primary, Lainchbury, Michael, primary, Matthews, Thomas P., primary, Jamin, Yann, primary, Robinson, Simon P., primary, Aherne, G. Wynne, primary, Reader, John C., primary, Chesler, Louis, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Methods from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

Author

Renshaw, Jane, primary, Taylor, Kathryn R., primary, Bishop, Ryan, primary, Valenti, Melanie, primary, De Haven Brandon, Alexis, primary, Gowan, Sharon, primary, Eccles, Suzanne A., primary, Ruddle, Ruth R., primary, Johnson, Louise D., primary, Raynaud, Florence I., primary, Selfe, Joanna L., primary, Thway, Khin, primary, Pietsch, Torsten, primary, Pearson, Andrew D., primary, and Shipley, Janet, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 1 from The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Author

Walton, Michael I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie, primary, De Haven Brandon, Alexis, primary, Box, Gary, primary, Boxall, Kathy J., primary, Aherne, G. Wynne, primary, Eccles, Suzanne A., primary, Raynaud, Florence I., primary, Williams, David H., primary, Reader, John C., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Tables 3 - 6 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Author

Walton, Mike I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie R., primary, De Haven Brandon, Alexis K., primary, Box, Gary, primary, Hallsworth, Albert, primary, Smith, Elizabeth L., primary, Boxall, Kathy J., primary, Lainchbury, Michael, primary, Matthews, Thomas P., primary, Jamin, Yann, primary, Robinson, Simon P., primary, Aherne, G. Wynne, primary, Reader, John C., primary, Chesler, Louis, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Methods, Figure Legends 1-7 from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Author

Yap, Timothy A., primary, Walton, Mike I., primary, Grimshaw, Kyla M., primary, te Poele, Robert H., primary, Eve, Paul D., primary, Valenti, Melanie R., primary, de Haven Brandon, Alexis K., primary, Martins, Vanessa, primary, Zetterlund, Anna, primary, Heaton, Simon P., primary, Heinzmann, Kathrin, primary, Jones, Paul S., primary, Feltell, Ruth E., primary, Reule, Matthias, primary, Woodhead, Steven J., primary, Davies, Thomas G., primary, Lyons, John F., primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Workman, Paul, primary, Thompson, Neil T., primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 1 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Author

Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Patel, Sonal, primary, Alix, Sonia, primary, Box, Gary, primary, Chuckowree, Irina, primary, Folkes, Adrian, primary, Gowan, Sharon, primary, De Haven Brandon, Alexis, primary, Di Stefano, Francesca, primary, Hayes, Angela, primary, Henley, Alan T., primary, Lensun, Letitia, primary, Pergl-Wilson, Giles, primary, Robson, Anthony, primary, Saghir, Nahid, primary, Zhyvoloup, Alexander, primary, McDonald, Edward, primary, Sheldrake, Peter, primary, Shuttleworth, Stephen, primary, Valenti, Melanie, primary, Wan, Nan Chi, primary, Clarke, Paul A., primary, and Workman, Paul, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 2 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Author

Walton, Mike I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie R., primary, De Haven Brandon, Alexis K., primary, Box, Gary, primary, Hallsworth, Albert, primary, Smith, Elizabeth L., primary, Boxall, Kathy J., primary, Lainchbury, Michael, primary, Matthews, Thomas P., primary, Jamin, Yann, primary, Robinson, Simon P., primary, Aherne, G. Wynne, primary, Reader, John C., primary, Chesler, Louis, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

45. Data from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Author

Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Patel, Sonal, primary, Alix, Sonia, primary, Box, Gary, primary, Chuckowree, Irina, primary, Folkes, Adrian, primary, Gowan, Sharon, primary, De Haven Brandon, Alexis, primary, Di Stefano, Francesca, primary, Hayes, Angela, primary, Henley, Alan T., primary, Lensun, Letitia, primary, Pergl-Wilson, Giles, primary, Robson, Anthony, primary, Saghir, Nahid, primary, Zhyvoloup, Alexander, primary, McDonald, Edward, primary, Sheldrake, Peter, primary, Shuttleworth, Stephen, primary, Valenti, Melanie, primary, Wan, Nan Chi, primary, Clarke, Paul A., primary, and Workman, Paul, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 1 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Author

Walton, Mike I., primary, Eve, Paul D., primary, Hayes, Angela, primary, Valenti, Melanie R., primary, De Haven Brandon, Alexis K., primary, Box, Gary, primary, Hallsworth, Albert, primary, Smith, Elizabeth L., primary, Boxall, Kathy J., primary, Lainchbury, Michael, primary, Matthews, Thomas P., primary, Jamin, Yann, primary, Robinson, Simon P., primary, Aherne, G. Wynne, primary, Reader, John C., primary, Chesler, Louis, primary, Raynaud, Florence I., primary, Eccles, Suzanne A., primary, Collins, Ian, primary, and Garrett, Michelle D., primary

Published
2023
Full Text
View/download PDF

47. Data from NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

Author

Eccles, Suzanne A., primary, Massey, Andy, primary, Raynaud, Florence I., primary, Sharp, Swee Y., primary, Box, Gary, primary, Valenti, Melanie, primary, Patterson, Lisa, primary, de Haven Brandon, Alexis, primary, Gowan, Sharon, primary, Boxall, Frances, primary, Aherne, Wynne, primary, Rowlands, Martin, primary, Hayes, Angela, primary, Martins, Vanessa, primary, Urban, Frederique, primary, Boxall, Kathy, primary, Prodromou, Chrisostomos, primary, Pearl, Laurence, primary, James, Karen, primary, Matthews, Thomas P., primary, Cheung, Kwai-Ming, primary, Kalusa, Andrew, primary, Jones, Keith, primary, McDonald, Edward, primary, Barril, Xavier, primary, Brough, Paul A., primary, Cansfield, Julie E., primary, Dymock, Brian, primary, Drysdale, Martin J., primary, Finch, Harry, primary, Howes, Rob, primary, Hubbard, Roderick E., primary, Surgenor, Alan, primary, Webb, Paul, primary, Wood, Mike, primary, Wright, Lisa, primary, and Workman, Paul, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figures 1-2 from Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Author

Raynaud, Florence I., primary, Eccles, Suzanne, primary, Clarke, Paul A., primary, Hayes, Angela, primary, Nutley, Bernard, primary, Alix, Sonia, primary, Henley, Alan, primary, Di-Stefano, Francesca, primary, Ahmad, Zahida, primary, Guillard, Sandrine, primary, Bjerke, Lynn M., primary, Kelland, Lloyd, primary, Valenti, Melanie, primary, Patterson, Lisa, primary, Gowan, Sharon, primary, de Haven Brandon, Alexis, primary, Hayakawa, Masahiko, primary, Kaizawa, Hiroyuki, primary, Koizumi, Tomonubu, primary, Ohishi, Takahide, primary, Patel, Sonal, primary, Saghir, Nahid, primary, Parker, Peter, primary, Waterfield, Mike, primary, and Workman, Paul, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Materials, Figure Legends 1-6, Tables 1-5 from NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

Author

Eccles, Suzanne A., primary, Massey, Andy, primary, Raynaud, Florence I., primary, Sharp, Swee Y., primary, Box, Gary, primary, Valenti, Melanie, primary, Patterson, Lisa, primary, de Haven Brandon, Alexis, primary, Gowan, Sharon, primary, Boxall, Frances, primary, Aherne, Wynne, primary, Rowlands, Martin, primary, Hayes, Angela, primary, Martins, Vanessa, primary, Urban, Frederique, primary, Boxall, Kathy, primary, Prodromou, Chrisostomos, primary, Pearl, Laurence, primary, James, Karen, primary, Matthews, Thomas P., primary, Cheung, Kwai-Ming, primary, Kalusa, Andrew, primary, Jones, Keith, primary, McDonald, Edward, primary, Barril, Xavier, primary, Brough, Paul A., primary, Cansfield, Julie E., primary, Dymock, Brian, primary, Drysdale, Martin J., primary, Finch, Harry, primary, Howes, Rob, primary, Hubbard, Roderick E., primary, Surgenor, Alan, primary, Webb, Paul, primary, Wood, Mike, primary, Wright, Lisa, primary, and Workman, Paul, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 2 from NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

Author

Eccles, Suzanne A., primary, Massey, Andy, primary, Raynaud, Florence I., primary, Sharp, Swee Y., primary, Box, Gary, primary, Valenti, Melanie, primary, Patterson, Lisa, primary, de Haven Brandon, Alexis, primary, Gowan, Sharon, primary, Boxall, Frances, primary, Aherne, Wynne, primary, Rowlands, Martin, primary, Hayes, Angela, primary, Martins, Vanessa, primary, Urban, Frederique, primary, Boxall, Kathy, primary, Prodromou, Chrisostomos, primary, Pearl, Laurence, primary, James, Karen, primary, Matthews, Thomas P., primary, Cheung, Kwai-Ming, primary, Kalusa, Andrew, primary, Jones, Keith, primary, McDonald, Edward, primary, Barril, Xavier, primary, Brough, Paul A., primary, Cansfield, Julie E., primary, Dymock, Brian, primary, Drysdale, Martin J., primary, Finch, Harry, primary, Howes, Rob, primary, Hubbard, Roderick E., primary, Surgenor, Alan, primary, Webb, Paul, primary, Wood, Mike, primary, Wright, Lisa, primary, and Workman, Paul, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results